Snezhina Lazova1,2, Stamatios Priftis3, Guergana Petrova4, Emilia Naseva5, Tsvetelina Velikova6. 1. Pediatric Department, UMHATEM "N. I. Pirogov" 21 Blvd Totleben, 1606 Sofia, Bulgaria. 2. Healthcare Department, Faculty of Public Health, Medical University of Sofia 8 Bialo More Street, 1577 Sofia, Bulgaria. 3. Faculty of Public Health, Medical University of Sofia, Health Technology Assessment Department 8 Bialo More Street, 1527 Sofia, Bulgaria. 4. Medical University, Pediatric Clinic, UMHAT Alexandrovska 1 Georgi Sofiyski Street, 1431 Sofia, Bulgaria. 5. Faculty of Public Health, Medical University of Sofia, Health Economics Department 8 Bialo More Street, 1527 Sofia, Bulgaria. 6. University Hospital Lozenetz, Sofia University - Medical Faculty 1 Kozyak Street, 1407 Sofia, Bulgaria.
Abstract
(1) Background: Several recent studies on the clinical value of spirometry indexes demonstrated high sensitivity of FEF25-75 as a marker of bronchial obstruction in asthmatics with normal baseline spirometry. Our study aims to evaluate the clinical value of maximal mid-expiratory flow in children with asthma. (2) Methods: For two years, 257 children were included - 211 with asthma and 46 healthy controls. Pre- and post-bronchodilator spirometry, atopic status determination and asthma control assessment were performed. (3) Results: The small airway obstruction (SAO) group (FEV1≥80%, ММEF25/75<65%) demonstrated significantly lower values for FEV1, FEV1/FVC, PEFR, МMMF25/75 and a significant higher bronchodilator response (BDR, ΔFEV1% init. ≥12%) compared to normal baseline spirometry group (FEV1>80%, MMEF25/75≥65%) (Р<0.0001). In addition, we found a statistically significant difference in FEF25-75/FVC median between asthmatics and healthy controls (Р<0.0001) regardless of the FEV1 value. Children with SAO have a 2.338-fold higher risk of poor asthma outcome (OR 95% CI [1.077-5.294]) and a 6.171-fold (OR 95% CI [2.523-15.096]) greater probability of demonstrating positive BDR, compared to children with normal baseline spirometry. MMEF25/75 was found to be a good predictor for positive BDR with AUC 0.843 (CI 0.781-0.845) and a best cut-off value of 58.1% (77.8% sensitivity and 78.8% specificity). (4) Conclusion: Our results confirmed that a small but substantial group of asthmatic children with normal baseline FEV1 and low MMEF25-75 are at higher risk for poor asthma outcomes. IJPPP
(1) Background: Several recent studies on the clinical value of spirometry indexes demonstrated high sensitivity of FEF25-75 as a marker of bronchial obstruction in asthmatics with normal baseline spirometry. Our study aims to evaluate the clinical value of maximal mid-expiratory flow in children with asthma. (2) Methods: For two years, 257 children were included - 211 with asthma and 46 healthy controls. Pre- and post-bronchodilator spirometry, atopic status determination and asthma control assessment were performed. (3) Results: The small airway obstruction (SAO) group (FEV1≥80%, ММEF25/75<65%) demonstrated significantly lower values for FEV1, FEV1/FVC, PEFR, МMMF25/75 and a significant higher bronchodilator response (BDR, ΔFEV1% init. ≥12%) compared to normal baseline spirometry group (FEV1>80%, MMEF25/75≥65%) (Р<0.0001). In addition, we found a statistically significant difference in FEF25-75/FVC median between asthmatics and healthy controls (Р<0.0001) regardless of the FEV1 value. Children with SAO have a 2.338-fold higher risk of poor asthma outcome (OR 95% CI [1.077-5.294]) and a 6.171-fold (OR 95% CI [2.523-15.096]) greater probability of demonstrating positive BDR, compared to children with normal baseline spirometry. MMEF25/75 was found to be a good predictor for positive BDR with AUC 0.843 (CI 0.781-0.845) and a best cut-off value of 58.1% (77.8% sensitivity and 78.8% specificity). (4) Conclusion: Our results confirmed that a small but substantial group of asthmatic children with normal baseline FEV1 and low MMEF25-75 are at higher risk for poor asthma outcomes. IJPPP
Authors: Philip H Quanjer; Daniel J Weiner; Jeffrey J Pretto; Danny J Brazzale; Piotr W Boros Journal: Eur Respir J Date: 2013-09-26 Impact factor: 16.671
Authors: Watcharoot Kanchongkittiphon; Jonathan M Gaffin; Lianne Kopel; Carter R Petty; Mary E Bollinger; Rachel L Miller; Matthew Perzanowski; Elizabeth C Matsui; Wanda Phipatanakul Journal: Ann Allergy Asthma Immunol Date: 2016-05-26 Impact factor: 6.347
Authors: A L Fuhlbrigge; B T Kitch; A D Paltiel; K M Kuntz; P J Neumann; D W Dockery; S T Weiss Journal: J Allergy Clin Immunol Date: 2001-01 Impact factor: 10.793
Authors: Michael R Simon; Vernon M Chinchilli; Brenda R Phillips; Christine A Sorkness; Robert F Lemanske; Stanley J Szefler; Lynn Taussig; Leonard B Bacharier; Wayne Morgan Journal: J Allergy Clin Immunol Date: 2010-07-16 Impact factor: 10.793
Authors: Leonard B Bacharier; Robert C Strunk; David Mauger; Deborah White; Robert F Lemanske; Christine A Sorkness Journal: Am J Respir Crit Care Med Date: 2004-06-01 Impact factor: 21.405